MCT8 deficiency drug withdrawal trial raises questions about lifelong treatment
NCT ID NCT05579327
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 study looked at what happens when males with MCT8 deficiency (a rare genetic condition affecting thyroid hormone transport) stop taking tiratricol. Twenty participants who had been stable on tiratricol were randomly assigned to either continue the drug or receive a placebo for 30 days. The main goal was to see if stopping tiratricol causes a rise in T3 hormone levels, which could signal the need to restart treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tiratricol
- What this could lead to
- If successful, this study could confirm that tiratricol is essential for controlling thyroid hormone levels in MCT8 deficiency, supporting its continued use as a maintenance treatment.
- What could go wrong
- This is a small, short-term withdrawal study (30 days) with only 20 participants. It does not test long-term benefits or safety, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLAN-HERNDON-DUDLEY SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Addenbrooke's Hospital
Cambridge, United Kingdom
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Erasmus MC
Rotterdam, 3015 GD, Netherlands
-
Rare Disease Research, LLC
Kissimmee, Florida, 34746, United States
-
Rare Disease Research, LLC
Atlanta, Georgia, 30329, United States
-
Rare Disease Research, LLC
Hillsborough, North Carolina, 27278, United States
-
SSM Health Cardinal Glennon Children's Hospital
St Louis, Missouri, 63104, United States
-
Tranquil Clinical and Research Consulting Services
Webster, Texas, 77598, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.